Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2015/587893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551497844391936 |
|---|---|
| author | Oscar D. Bruno Lea Juárez-Allen Silvia B. Christiansen Marcos Manavela Karina Danilowicz Carlos Vigovich Reynaldo M. Gómez |
| author_facet | Oscar D. Bruno Lea Juárez-Allen Silvia B. Christiansen Marcos Manavela Karina Danilowicz Carlos Vigovich Reynaldo M. Gómez |
| author_sort | Oscar D. Bruno |
| collection | DOAJ |
| description | We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson’s syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing’s disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration. |
| format | Article |
| id | doaj-art-db10d8da2e7a4a349c688910e2708307 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-db10d8da2e7a4a349c688910e27083072025-02-03T06:01:24ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/587893587893Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from ArgentinaOscar D. Bruno0Lea Juárez-Allen1Silvia B. Christiansen2Marcos Manavela3Karina Danilowicz4Carlos Vigovich5Reynaldo M. Gómez6Foundation of Endocrinology, 1425 Buenos Aires, ArgentinaFoundation of Endocrinology, 1425 Buenos Aires, ArgentinaPathology Laboratory, Hospital Italiano, 1199 Buenos Aires, ArgentinaDivision of Endocrinology, Hospital de Clínicas, University of Buenos Aires, 1120 Buenos Aires, ArgentinaDivision of Endocrinology, Hospital de Clínicas, University of Buenos Aires, 1120 Buenos Aires, ArgentinaDivision of Endocrinology, Hospital de Clínicas, University of Buenos Aires, 1120 Buenos Aires, ArgentinaDivision of Endocrinology, Hospital de Clínicas, University of Buenos Aires, 1120 Buenos Aires, ArgentinaWe evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson’s syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing’s disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration.http://dx.doi.org/10.1155/2015/587893 |
| spellingShingle | Oscar D. Bruno Lea Juárez-Allen Silvia B. Christiansen Marcos Manavela Karina Danilowicz Carlos Vigovich Reynaldo M. Gómez Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina International Journal of Endocrinology |
| title | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
| title_full | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
| title_fullStr | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
| title_full_unstemmed | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
| title_short | Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina |
| title_sort | temozolomide therapy for aggressive pituitary tumors results in a small series of patients from argentina |
| url | http://dx.doi.org/10.1155/2015/587893 |
| work_keys_str_mv | AT oscardbruno temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT leajuarezallen temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT silviabchristiansen temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT marcosmanavela temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT karinadanilowicz temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT carlosvigovich temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina AT reynaldomgomez temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina |